

July 10, 2026

## KIMS Healthcare Management Limited: Update on Material Event

### Summary of rating(s) outstanding

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating outstanding	Financial sector regulator <sup>#</sup>
Long-term – Fund-based/ Cash Credit	19.00	19.00	[ICRA]AA- Rating Watch with Developing Implications	RBI
Long-term – Fund-based/ Term Loan	75.00	75.00	[ICRA]AA- Rating Watch with Developing Implications	RBI
Short-term – Non-fund Based - Others	12.00	12.00	[ICRA]A1+; Rating Watch with Developing Implications	RBI
Long-term/ Short term – Unallocated	104.00	104.00	[ICRA]AA- Rating Watch with Developing Implications / [ICRA]A1+; Rating Watch with Developing Implications	RBI
<b>Total</b>	<b>210.00</b>	<b>210.00</b>		

\*Instrument details are provided in Annexure I

<sup>#</sup>SEBI's grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.

### Rationale

#### Material Event

ICRA notes that Quality Care India Limited (QCIL), the parent entity of KIMS Healthcare Management Limited (KHML), has been amalgamated with Aster DM Healthcare Limited (ADMHL), effective July 1, 2026. The completion of the transaction was duly intimated to the stock exchanges by ADMHL. The merged entity, Aster DM Quality Care Limited (ADMQL), will be the major shareholder in KHML with stake of around 90%. ADMQL is expected to benefit from a significantly larger scale of operations, a wider geographical presence across key healthcare markets, enhanced diversification in revenue streams, and a strengthened competitive position in the domestic healthcare sector.

The ratings of KHML had earlier been placed on Watch with Developing Implications to monitor the impact of the expected change in the ownership structure on KHML's credit profile.

#### Impact of Material Event

ICRA has noted QCIL's merger with ADMHL. KHML is expected to be strategically important to the Group, given its established market presence in Trivandrum and surrounding region, reflected in its healthy operating and financial profiles. The Rating Watch is expected to be resolved as better clarity emerges on the parent's support philosophy towards KHML, any material shift in KHML's business strategies or financial policies and on the entity's recent financial performance.

Please refer to the following link for the previous detailed rationale that captures Key rating drivers and their description, Liquidity position, Rating sensitivities, Key financial indicators: [Click here](#)

## Analytical approach

Analytical approach	Comments
Applicable rating methodologies	<a href="#">Corporate Credit Rating Methodology Hospitals</a>
Parent/Group support	As on September 30, 2025, QCIL held a 23.7% in KHML and a 90.3% in CIHPL, which, in turn, held a 61.5% in KHML. ICRA notes that the new parent would be ADMQCL.
Consolidation/Standalone	For arriving at the ratings, ICRA has taken a consolidated view of KIMS Healthcare Management Limited and KIMS Nagercoil Institute of Medical Sciences Private Limited and considered the consolidated financials of KHML. As on March 31, 2025, KHML had six subsidiaries, which are enlisted in Annexure-II.

## About the company

KHML was set up in 2002 by a group of professionals in Trivandrum. It is a tertiary and quaternary-care hospital, with 40 speciality departments. The hospital has been accredited by the National Accreditation Board for Hospitals (NABH), the Australian Council on Healthcare Standard International (ACHSI), and the National Accreditation Board for Laboratories (NABL). As on December 31, 2025, the company had five operational hospitals, spread across Trivandrum, Kottayam, Kollam, Perinthalmanna in Kerala and Nagercoil in Tamil Nadu with a total capacity of 1,560 beds.

KIMS Nagercoil Institute of Medical Sciences Private Limited (KNIMSPL), incorporated in 2014, operates a multi-specialty hospital in Nagercoil, Tamil Nadu, offering tertiary healthcare services. A wholly-owned subsidiary of KHML, the hospital caters to Nagercoil and surrounding districts and is accredited by NABH. Developed as a greenfield project, the hospital commenced operations in October 2024 with 80-85 beds, which expanded to 210 beds by December 2025. The project entailed a cost of around Rs. 150 crore, funded through term debt of Rs. 90 crore and the balance via equity infusion from KHML.

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

### Rating history for past three years

Current (FY2027)			Chronology of rating history for the past 3 years						
Instrument	Type	Amount rated (Rs. crore)	FY2026		FY2025		FY2024		
			Jul 10, 2026	Date	Rating	Date	Rating	Date	Rating
Term loans	Long term	75.00	[ICRA]AA-; Rating Watch with Developing Implications	Jan 19, 2026	[ICRA]AA-; Rating Watch with Developing Implications	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)
			-	-	-	-	-	Nov 06, 2023	[ICRA]A; Rating watch with Developing Implications
Cash credit	Long term	19.00	[ICRA]AA-; Rating Watch with Developing Implications	Jan 19, 2026	-	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)
			-	-	-	-	-	Nov 06, 2023	[ICRA]A; Rating watch with Developing Implications
BG/LC	Long term / Short term	0.00	-	-	-	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications / [ICRA]A1; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)/ [ICRA]A2+
			-	-	-	-	-	Nov 06, 2023	[ICRA]A; Rating watch with Developing Implications / [ICRA]A2+; Rating watch with Developing Implications
Non-fund Based – Others	Short-term	12.00	[ICRA]A1+; Rating Watch with Developing Implications	Jan 19, 2026	[ICRA]A1+; Rating Watch with Developing Implications	-	-	-	-
Unallocated	Long term / Short term	104.00	[ICRA]AA-; Rating Watch with Developing Implications/ [ICRA]A1+; Rating Watch with Developing Implications	Jan 19, 2026	[ICRA]AA-; Rating Watch with Developing Implications/ [ICRA]A1+; Rating Watch with Developing Implications	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications/ [ICRA]A1; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)/ [ICRA]A2+
			-	-	-	-	-	Nov 06, 2023	[ICRA]A; Rating watch with

Current (FY2027)			Chronology of rating history for the past 3 years						
Instrument	Type	Amount rated (Rs. crore)	FY2026		FY2025		FY2024		
			Jul 10, 2026	Date	Rating	Date	Rating	Date	Rating
									Developing Implications / [ICRA]A2+; Rating watch with Developing Implications

### Complexity level of the rated instrument

Instrument	Complexity indicator
Long-term – Fund-based/ Cash credit	Simple
Long-term – Fund-based/ Term loan	Simple
Short-term – Non-fund based – Others	Simple
Long-term/ Short-term – Unallocated	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

### Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook	Financial sector regulator
NA	Term loan	FY2020	NA	FY2030	75.00	[ICRA]AA-; Rating Watch with Developing Implications	RBI
NA	Cash credit	NA	NA	NA	19.0	[ICRA]AA-; Rating Watch with Developing Implications	RBI
NA	Bank guarantee	NA	NA	NA	6.0	[ICRA]A1+; Rating Watch with Developing Implications	RBI
NA	Letter of credit	NA	NA	NA	6.0	[ICRA]A1+; Rating Watch with Developing Implications	RBI
NA	Unallocated limits	NA	NA	NA	104.00	[ICRA]AA-; Rating Watch with Developing Implications / [ICRA]A1+; Rating Watch with Developing Implications	RBI

Source: Company

\*SEBI's grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.

[Please click here to view details of lender-wise facilities rated by ICRA](#)

**Annexure II: List of entities considered for consolidated analysis**

<b>Company name</b>	<b>KHML Ownership</b>	<b>Consolidation approach</b>
<b>KIMS Healthcare Management Limited</b>	100.0% (rated entity)	Full Consolidation
<b>KIMS Al Shifa Healthcare Private Limited</b>	51.0%	Full Consolidation
<b>KIMS Kottayam Institute of Medical Sciences Private Limited</b>	100.0%	Full Consolidation
<b>KIMS Kollam Multi Specialty Hospital India Private Limited</b>	100.0%	Full Consolidation
<b>KIMS Nagercoil Institute of Medical Sciences Private Limited</b>	100.0%	Full Consolidation
<b>Spiceretreat Hospitality Services Private Limited</b>	100.0%	Full Consolidation
<b>KIMS HEALTH Executive Leisure Private Limited</b>	100.0%	Full Consolidation

Source: KHML; Stake as on September 30, 2025

Note: ICRA has considered consolidated financials of the KHML and its subsidiaries while assigning the ratings.

## ANALYST CONTACTS

**Jitin Makkar**

0124 4545 368

[jitinm@icraindia.com](mailto:jitinm@icraindia.com)

**Srikumar K**

+91 44 4596 4318

[ksrikumar@icraindia.com](mailto:ksrikumar@icraindia.com)

**Nithya Debbadi**

+91 40 6939 6416

[nithya.debbadi@icraindia.com](mailto:nithya.debbadi@icraindia.com)

**Raviteja Etikala**

+91 40 6939 6418

[etikala.teja@icraindia.com](mailto:etikala.teja@icraindia.com)

## RELATIONSHIP CONTACT

**L. Shivakumar**

+91 22 6114 3406

[shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**

Tel: +91 124 4545 860

[communications@icraindia.com](mailto:communications@icraindia.com)

## HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited




### Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001  
Tel: +91 11 23357940-45



### Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.